ClinicalTrials.gg
CompletedNCT00615056Updated Apr 19, 2013Results posted

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

A Phase 2 interventional study of Bevacizumab (avastin) and FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) in Colorectal Neoplasms, sponsored by Pfizer. Completed at 83 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-19.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing Folfox protocol in Colorectal Neoplasms — 14 open to participants now, 17 under way, 3 of them phase 3. Folfox protocol · Colorectal Neoplasms.

Enrollment
12th of 37
171 · median 102
Started
2008
the only one that year
Phase 2
19 of 37
8 open now
Registered
5th of 37
by date
Lead sponsor
2 of 37
Pfizer

Among the 37 studies testing Folfox protocol in Colorectal Neoplasms, this one is the 12th largest by enrollment, is the only one that started in 2008, is one of 19 in phase 2, and was the 5th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

14 of the 37 studies testing Folfox protocol in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Folfox protocol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing Folfox protocol in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented colorectal cancer plus one of the following:
  • Failure of one prior irinotecan- or oxaliplatin-containing regimen, or
  • Adjuvant to irinotecan- or oxaliplatin-containing regimen.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment in setting with more than one regimen
  • Prior irradiation of more than 25% of bone marrow.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Active comparator
    B

    Bevacizumab (avastin)

    Drug: Bevacizumab (avastin) · Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])

  • Experimental
    C

    AG-013736 (axitinib)

    Drug: AG-013736 (axitinib) · Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])

  • Experimental
    A

    AG-013736 (axitinib)

    Drug: AG-013736 (axitinib) · Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])

  • Active comparator
    D

    bevacizumab (avastin)

    Drug: Bevacizumab (avastin) · Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])

Interventions

  • Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.

  • DrugFOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])

    Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

  • Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.

  • Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

  • Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.

  • DrugFOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])

    Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

  • Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.

  • Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 week up to 130 weeks

Secondary outcomes

  1. Overall Survival (OS)

    Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death or up to 1 year after the randomization of last participant

  2. Percentage of Participants With Objective Response (OR)

    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

    Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks

  3. Duration of Response (DR)

    Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks

  4. Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

    Symptom severity score is comprised of average of 14 MDASI-D core items (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling and diarrhea) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last week; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome. Total average score range: 0 to 10.

    Time frame: Baseline, Day 1 of cycles 2- 5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal

  5. Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

    Symptom Interference score is comprised of the average of 6 items on feeling or function from the MDASI-D core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last week; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome. Total average score range: 0 to 10.

    Time frame: Baseline, Day 1 of cycle 2-5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal

07

Results

Posted Apr 20, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Started49513635
Treated46513635
Completed0000
Not completed49513635
Withdrew: Death31312123
Withdrew: Lost to follow-up1245
Withdrew: Other1315107
Withdrew: Objective progression or relapse0200
Withdrew: Withdrawal by subject0110
Withdrew: Discontinued by sponsor1000
Withdrew: Randomized but not treated3000

Outcome measures

PrimaryProgression Free Survival (PFS)

Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 week up to 130 weeks
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Progression Free Survival (PFS)5.72 (4.50 to 7.42)6.87 (4.96 to 9.13)7.59 (5.62 to 11.07)6.44 (5.52 to 13.11)
Statistical analysis
  • Axitinib + FOLFIRI vs Bevacizumab + FOLFIRI · Log Rank · p = 0.8268 (One-sided log-rank test at alpha = 0.15 significance level was used.) · Hazard ratio (hr): 1.273 · 95% CI 0.769 to 2.108
  • Axitinib + FOLFOX vs Bevacizumab + FOLFOX · Log Rank · p = 0.5498 (One-sided log-rank test at alpha = 0.15 significance level was used.) · Hazard ratio (hr): 1.041 · 95% CI 0.553 to 1.041
SecondaryOverall Survival (OS)

Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death or up to 1 year after the randomization of last participant
Reported as:
Median · Months
Overall Survival (OS)
MonthsAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Overall Survival (OS)12.9 (10.2 to 16.6)15.7 (12.1 to 23.0)17.1 (10.1 to 23.0)14.1 (9.0 to 16.4)
Statistical analysis
  • Axitinib + FOLFIRI vs Bevacizumab + FOLFIRI · Log Rank · p = 0.8828 (One-sided log-rank test at alpha = 0.15 significance level was used.) · Hazard ratio (hr): 1.355 · 95% CI 0.820 to 2.238
  • Axitinib + FOLFOX vs Bevacizumab + FOLFOX · Log Rank · p = 0.1159 (One-sided log-rank test at alpha = 0.15 significance level was used.) · Hazard ratio (hr): 0.689 · 95% CI 0.373 to 1.273
SecondaryPercentage of Participants With Objective Response (OR)

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

Time frame:
Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Percentage of Participants With Objective Response (OR)24.5 (13.3 to 38.9)23.5 (12.8 to 37.5)19.4 (8.2 to 36.0)20.0 (8.4 to 36.9)
Statistical analysis
  • Axitinib + FOLFIRI vs Bevacizumab + FOLFIRI · Chi-squared · p = 0.4552 · Mean difference (final values): 1 · 95% CI -15.8 to 17.7
  • Axitinib + FOLFOX vs Bevacizumab + FOLFOX · Chi-squared · p = 0.5235 · Mean difference (final values): -0.6 · 95% CI -19.1 to 18.0
SecondaryDuration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until disease progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 130 weeks
Reported as:
Median · Months
Duration of Response (DR)
MonthsAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Duration of Response (DR)7.52 (5.22 to NA)12.29 (7.39 to 12.84)10.15 (4.17 to 12.91)10.94 (4.53 to 12.68)
SecondaryChange From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

Symptom severity score is comprised of average of 14 MDASI-D core items (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling and diarrhea) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last week; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome. Total average score range: 0 to 10.

Time frame:
Baseline, Day 1 of cycles 2- 5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal
Reported as:
Mean · Units on a Scale
Change From Baseline in MD Anderson Symptoms Inventory Diarrhea (MDASI-D) Symptom Severity Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
Units on a ScaleAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Baseline (n=39,46,35,33)2.1 (1.6 to 2.6)1.8 (1.3 to 2.2)1.9 (1.3 to 2.5)2.0 (1.4 to 2.7)
Change at Cycle 2/Day 1 (n=35, 39, 34,28)0.6 (0.2 to 1.1)0.5 (-0.1 to 1.0)0.7 (0.2 to 1.2)0.0 (-0.4 to 0.5)
Change at Cycle 3/Day 1 (n=36,36,33,26)0.8 (0.2 to 1.4)0.2 (-0.3 to 0.6)0.3 (-0.4 to 1.0)0.2 (-0.3 to 0.7)
Change at Cycle 4/Day 1 (n=29,37,32,25)0.8 (0.0 to 1.5)0.0 (-0.4 to 0.5)0.5 (-0.2 to 1.1)0.5 (-0.1 to 1.1)
Change at Cycle 5/Day 1 (n=28,29,24,24)0.5 (0.0 to 1.1)0.1 (-0.4 to 0.7)0.9 (0.2 to 1.7)0.4 (-0.2 to 0.9)
Change at Cycle 7/Day 1 (n=26,31,22,20)0.7 (0.1 to 1.2)0.0 (-0.6 to 0.5)0.6 (0.1 to 1.1)0.2 (-0.5 to 0.9)
Change at Cycle 9/Day 1 (n=19,26,19,17)1.1 (0.3 to 1.9)-0.2 (-0.7 to 0.2)0.6 (-0.1 to 1.3)0.8 (0.3 to 1.3)
Change at Cycle 11/Day 1 (n=15,24,16,15)1.0 (0.1 to 1.9)0.1 (-0.5 to 0.7)1.0 (0.2 to 1.8)0.1 (-0.8 to 1.1)
Change at Cycle 13/Day 1 (n=13,19,15,10)1.0 (-0.5 to 2.6)0.1 (-0.6 to 0.7)0.9 (0.2 to 1.6)0.8 (0.1 to 1.4)
Change at Cycle 15/Day 1 (n=7,17,12,8)0.8 (-1.6 to 3.3)0.2 (-0.3 to 0.7)0.5 (-0.4 to 1.3)1.0 (0.4 to 1.6)
Change at Cycle 17/Day 1 (n=6,11,11,7)2.0 (-0.9 to 5.0)0.4 (-0.3 to 1.0)0.9 (0.1 to 1.8)1.7 (0.7 to 2.7)
Change at Cycle 19/Day 1 (n=6,10,9,5)1.3 (-1.5 to 4.1)0.5 (-0.7 to 1.7)0.8 (-0.2 to 1.8)1.4 (0.7 to 2.2)
Change at Cycle 21/Day 1 (n=6,9,7,4)1.1 (-2.2 to 4.4)0.5 (-0.5 to 1.5)0.9 (-0.9 to 2.7)1.6 (0.3 to 2.8)
Change at Cycle 23/Day 1 (n=5,7,6,4)2.6 (0.3 to 4.8)-0.3 (-0.9 to 0.3)0.4 (-1.4 to 2.3)1.0 (0.8 to 1.2)
Change at Cycle 25/Day 1 (n=5,7,6,3)2.2 (-1.2 to 5.6)0.1 (-1.2 to 1.4)0.2 (-2.0 to 2.3)1.0 (0.5 to 1.4)
Change at Cycle 27/Day 1 (n=2,7,3,3)2.3 (-20.8 to 25.5)0.4 (-1.4 to 2.3)0.3 (-5.4 to 5.9)1.1 (0.6 to 1.5)
Change at Cycle 29/Day 1 (n=2,5,2,3)2.8 (-25.8 to 31.4)-0.2 (-1.3 to 0.9)-0.8 (-1.7 to 0.1)0.9 (-0.3 to 2.1)
Change at Cycle 31/Day 1 (n=1,5,2,2)4.9 (NA to NA)-0.4 (-1.2 to 0.3)-0.3 (-5.7 to 5.2)0.9 (-1.4 to 3.2)
Change at Cycle 33/Day 1 (n=1,3,2,1)5.0 (NA to NA)-0.6 (-3.2 to 2.0)-0.8 (-7.6 to 6.1)0.5 (NA to NA)
Change at Cycle 35/Day 1 (n=0,4,1,1)NA (NA to NA)-0.4 (-1.5 to 0.7)0.4 (NA to NA)2.4 (NA to NA)
Change at Cycle 37/Day 1 (n=0,4,0,1)NA (NA to NA)-0.5 (-1.3 to 0.4)NA (NA to NA)1.0 (NA to NA)
Change at Cycle 39/Day 1 (n=0,2,0,1)NA (NA to NA)-0.4 (-0.8 to 0.1)NA (NA to NA)1.0 (NA to NA)
Change at Cycle 41/Day 1 (n=0,2,0,1)NA (NA to NA)-0.3 (-0.8 to 0.1)NA (NA to NA)1.4 (NA to NA)
Change at Cycle 43/Day 1 (n=0,1,0,1)NA (NA to NA)-0.4 (NA to NA)NA (NA to NA)2.0 (NA to NA)
Change at Cycle 45/Day 1 (n=0,0,0,1 )NA (NA to NA)NA (NA to NA)NA (NA to NA)2.2 (NA to NA)
Change at Cycle 47/Day 1 (n=0,1,0,0)NA (NA to NA)-0.4 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 49/Day 1 (n=0,1,0,0)NA (NA to NA)-0.5 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 51/Day 1 (n=0,1,0,0)NA (NA to NA)-0.4 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 53/Day 1 (n=0,1,0,0)NA (NA to NA)-0.4 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 55/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 57/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 59/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 61/Day 1 (n=0,1,0,0)NA (NA to NA)-0.2 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 63/Day 1 (n=0,0,0,0)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 65/Day 1 (n=0,1,0,0)NA (NA to NA)-0.4 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at end of treatment (n=21,29,27,22)0.7 (-0.2 to 1.6)0.5 (-0.1 to 1.0)1.3 (0.4 to 2.1)0.9 (0.1 to 1.7)
SecondaryChange From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal

Symptom Interference score is comprised of the average of 6 items on feeling or function from the MDASI-D core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last week; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome. Total average score range: 0 to 10.

Time frame:
Baseline, Day 1 of cycle 2-5, Day 1 of every odd-numbered cycle throughout the study and end of treatment (cycle 65) or withdrawal
Reported as:
Mean · Units on a Scale
Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal
Units on a ScaleAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
Baseline (n=39,46,35,33)2.1 (1.4 to 2.8)1.7 (1.1 to 2.3)2.4 (1.6 to 3.2)2.8 (1.8 to 3.9)
Change at Cycle 2/Day 1 (n=35, 39, 34, 28)0.8 (0.0 to 1.5)0.9 (0.2 to 1.6)0.1 (-0.6 to 0.7)-0.5 (-1.2 to 0.1)
Change at Cycle 3/Day 1 (n=36,36,33,26)1.3 (0.5 to 2.2)0.3 (-0.3 to 0.8)0.3 (-0.6 to 1.2)-0.2 (-1.0 to 0.6)
Change at Cycle 4/Day 1 (n=29,37,32,25)0.8 (-0.1 to 1.7)-0.2 (-0.9 to 0.4)0.2 (-0.6 to 1.1)0.5 (-0.2 to 1.3)
Change at Cycle 5/Day 1 (n=28,29,24,24)1.0 (0.3 to 1.6)0.4 (-0.7 to 1.4)0.8 (-0.4 to 2.0)0.3 (-0.6 to 1.2)
Change at Cycle 7/Day 1 (n=26,30,22,20)0.7 (-0.1 to 1.5)0.4 (-0.4 to 1.2)0.4 (-0.3 to 1.1)0.0 (-0.8 to 0.7)
Change at Cycle 9/Day 1 (n=18,25,19,17)1.1 (0.2 to 1.9)0.3 (-0.6 to 1.1)0.6 (-0.5 to 1.6)0.3 (-0.8 to 1.4)
Change at Cycle 11/Day 1 (n=15,24,16,15)1.0 (0.0 to 2.1)0.3 (-0.6 to 1.3)0.8 (0.0 to 1.6)-0.2 (-1.6 to 1.2)
Change at Cycle 13/Day 1 (n=13,19,15,10)1.1 (-0.4 to 2.7)0.7 (-0.2 to 1.5)1.3 (0.4 to 2.2)0.7 (-0.7 to 2.1)
Change at Cycle 15/Day 1 (n=7,17,12,8)2.3 (0.8 to 3.8)0.9 (-0.3 to 2.0)-0.1 (-1.4 to 1.3)1.3 (0.0 to 2.5)
Change at Cycle 17/Day 1 (n=6,11,11,7)2.4 (0.9 to 3.8)0.7 (-0.7 to 2.1)0.7 (-1.3 to 2.6)2.1 (-0.1 to 4.3)
Change at Cycle 19/Day 1 (n=6,10,9,5)2.1 (0.6 to 3.6)0.8 (-0.6 to 2.3)0.3 (-1.6 to 2.2)2.4 (1.2 to 3.7)
Change at Cycle 21/Day 1 (n=6,9,7,4)1.7 (-0.3 to 3.7)1.0 (-1.2 to 3.2)0.4 (-1.0 to 1.8)2.1 (0.8 to 3.4)
Change at Cycle 23/Day 1 (n=5,7,6,4)2.2 (0.0 to 4.4)-0.3 (-1.3 to 0.8)0.9 (-1.7 to 3.4)1.4 (0.8 to 2.0)
Change at Cycle 25/Day 1 (n=5,7,6,3)1.6 (-0.9 to 4.1)0.5 (-2.0 to 3.0)-0.6 (-2.7 to 1.5)1.4 (0.5 to 2.3)
Change at Cycle 27/Day 1 (n=2,7,3,3)1.6 (-16.4 to 19.6)0.9 (-2.1 to 4.0)-1.6 (-5.7 to 2.4)1.3 (0.9 to 1.7)
Change at Cycle 29/Day 1 (n=2,5,2,3)3.2 (-26.5 to 32.8)0.0 (-2.3 to 2.2)-1.3 (-15.0 to 12.5)1.3 (-0.4 to 3.0)
Change at Cycle 31/Day 1 (n=1,5,2,2)4.5 (NA to NA)-0.5 (-2.1 to 1.0)-0.1 (-26.6 to 26.4)1.2 (-3.1 to 5.4)
Change at Cycle 33/Day 1 (n=1,3,2,1)4.5 (NA to NA)-0.2 (-4.4 to 3.9)-0.8 (-29.3 to 27.8)0.3 (NA to NA)
Change at Cycle 35/Day 1 (n=0,4,1,1 )NA (NA to NA)-0.3 (-1.9 to 1.2)-1.2 (NA to NA)3.3 (NA to NA)
Change at Cycle 37/Day 1 (n=0,4,0,1)NA (NA to NA)-0.4 (-2.1 to 1.2)NA (NA to NA)1.3 (NA to NA)
Change at Cycle 39/Day 1 (n=0,2,0,1)NA (NA to NA)-0.3 (-0.3 to -0.3)NA (NA to NA)2.0 (NA to NA)
Change at Cycle 41/Day 1 (n=0,2,0,1)NA (NA to NA)-0.2 (-2.3 to 2.0)NA (NA to NA)1.5 (NA to NA)
Change at Cycle 43/Day 1 (n=0,1,0,1)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)1.8 (NA to NA)
Change at Cycle 45/Day 1 (n=0,0,0,1 )NA (NA to NA)NA (NA to NA)NA (NA to NA)2.5 (NA to NA)
Change at Cycle 47/Day 1 (n=0,1,0,0)NA (NA to NA)-0.2 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 49/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 51/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 53/Day 1 (n=0,1,0,0)NA (NA to NA)-0.2 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 55/Day 1 (n=0,1,0,0)NA (NA to NA)-0.3 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 57/Day 1 (n=0,1,0,0)NA (NA to NA)0.0 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 59/Day 1 (n=0,1,0,0)NA (NA to NA)-0.2 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 61/Day 1 (n=0,1,0,0)NA (NA to NA)0.0 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 63/Day 1 (n=0,0,0,0)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Change at Cycle 65/Day 1 (n=0,1,0,0)NA (NA to NA)-0.2 (NA to NA)NA (NA to NA)NA (NA to NA)
Change at end of treatment (n=21,29,26,21)1.3 (0.5 to 2.1)1.0 (0.3 to 1.6)1.5 (0.2 to 2.8)1.2 (0.0 to 2.4)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + FOLFIRI—17/46 (37%)45/46 (97.8%)
Bevacizumab + FOLFIRI—9/51 (17.6%)51/51 (100%)
Axitinib + FOLFOX—11/36 (30.6%)35/36 (97.2%)
Bevacizumab + FOLFOX—5/35 (14.3%)33/35 (94.3%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
DehydrationMetabolism and nutrition disorders4/460/511/360/35
DiarrhoeaGastrointestinal disorders3/462/510/361/35
Disease progressionGeneral disorders2/463/510/360/35
Abdominal painGastrointestinal disorders2/460/511/360/35
NauseaGastrointestinal disorders2/461/510/360/35
AstheniaGeneral disorders2/460/510/360/35
FatigueGeneral disorders2/460/511/360/35
HyperbilirubinaemiaHepatobiliary disorders2/460/510/360/35
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/461/510/360/35
VomitingGastrointestinal disorders1/462/511/360/35
Most frequent other events
Showing 10 of 344
Most frequent other events
EventAxitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOX
DiarrhoeaGastrointestinal disorders32/4625/5115/3611/35
HypertensionVascular disorders17/468/5124/366/35
NauseaGastrointestinal disorders27/4630/5118/3616/35
NeutropeniaBlood and lymphatic system disorders20/4627/5120/3610/35
Decreased appetiteMetabolism and nutrition disorders24/4616/5113/367/35
VomitingGastrointestinal disorders22/4618/5112/363/35
Neuropathy peripheralNervous system disorders3/464/517/3616/35
FatigueGeneral disorders21/4618/5112/369/35
ConstipationGastrointestinal disorders7/4616/513/3610/35
EpistaxisRespiratory, thoracic and mediastinal disorders11/4615/514/365/35

Baseline characteristics

Age, Customized
Age, Customized(Participants)Axitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOXTotal
18 to 44 years563115
45 to 64 years30342122107
Greater than and equal to 65 years1411121249
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + FOLFIRIBevacizumab + FOLFIRIAxitinib + FOLFOXBevacizumab + FOLFOXTotal
Female1824201173
Male3127162498
08

Study locations

83 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36608, United States
  • Pfizer Investigational Site
    Antioch, California 94531, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095-6984, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    Pleasant Hill, California 94523, United States
  • Pfizer Investigational Site
    San Leandro, California 94578, United States
  • Pfizer Investigational Site
    Santa Monica, California 90404, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Bonita Springs, Florida 34135, United States
  • Pfizer Investigational Site
    Bradenton, Florida 34209, United States
  • Pfizer Investigational Site
    Cape Coral, Florida 33914, United States
  • Pfizer Investigational Site
    Cape Coral, Florida 33990, United States
  • Pfizer Investigational Site
    Englewood, Florida 34223, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33901-8108, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33905, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33908, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33916, United States
  • Pfizer Investigational Site
    Naples, Florida 34102, United States
  • Pfizer Investigational Site
    Naples, Florida 34119, United States
  • Pfizer Investigational Site
    Port Charlotte, Florida 33980, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34232, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34236, United States
  • Pfizer Investigational Site
    Venice, Florida 34285, United States
  • Pfizer Investigational Site
    Venice, Florida 34292, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30318, United States
  • Pfizer Investigational Site
    Ringgold, Georgia 30736, United States
  • Pfizer Investigational Site
    Dubuque, Iowa 52001, United States
  • Pfizer Investigational Site
    Crestview Hills, Kentucky 41017, United States
  • Pfizer Investigational Site
    Paducah, Kentucky 42002, United States
  • Pfizer Investigational Site
    Paducah, Kentucky 42003, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21237, United States
  • Pfizer Investigational Site
    New Albany, Mississippi 38652, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45219, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45230, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45236, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45238, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45242, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45248, United States
  • Pfizer Investigational Site
    Fairfield, Ohio 45014, United States
  • Pfizer Investigational Site
    Hamilton, Ohio 45013, United States
  • Pfizer Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Pfizer Investigational Site
    Franklin, Tennessee 37067, United States
  • Pfizer Investigational Site
    Gallatin, Tennessee 37066, United States
  • Pfizer Investigational Site
    Germantown, Tennessee 38138, United States
  • Pfizer Investigational Site
    Hermitage, Tennessee 37076, United States
  • Pfizer Investigational Site
    Hixson, Tennessee 37343, United States
  • Pfizer Investigational Site
    Lebanon, Tennessee 37087, United States
  • Pfizer Investigational Site
    Murfreesboro, Tennessee 37130, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37205, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37207, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37211, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Paris, Tennessee 38242, United States
  • Pfizer Investigational Site
    Smyrna, Tennessee 37167, United States
  • Pfizer Investigational Site
    Union City, Tennessee 38261, United States
  • Pfizer Investigational Site
    Corpus Christi, Texas 78463, United States
  • Pfizer Investigational Site
    Mechanicsville, Virginia 23116, United States
  • Pfizer Investigational Site
    Midlothian, Virginia 23114, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23230, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23235, United States
  • Pfizer Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Pfizer Investigational Site
    Levis, Quebec G6V 3Z1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2X 3J4, Canada
  • Pfizer Investigational Site
    Lille, 59020, France
  • Pfizer Investigational Site
    Montpellier, 34094, France
  • Pfizer Investigational Site
    Paris, 75012, France
  • Pfizer Investigational Site
    Villejuif, 94805, France
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Padova, 35128, Italy
  • Pfizer Investigational Site
    Roma, 00152, Italy
  • Pfizer Investigational Site
    Roma, 00168, Italy
  • Pfizer Investigational Site
    Kashiwa, Chiba, Japan
  • Pfizer Investigational Site
    Suntougun, Shizuoka, Japan
  • Pfizer Investigational Site
    Chuo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Daegu, 700-721, Korea, Republic of
  • Pfizer Investigational Site
    Jeollanam-do, 519-809, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 139-706, Korea, Republic of
  • Pfizer Investigational Site
    Warszawa, 02-097, Poland
  • Pfizer Investigational Site
    Warszawa, 02-781, Poland
  • Pfizer Investigational Site
    L'hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Sabadell, Barcelona 08208, Spain
  • Pfizer Investigational Site
    Madrid, 28033, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Mar 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2008
First posted
Feb 14, 2008
Start
Mar 2008
Primary completionActual
Mar 2011
CompletionActual
Apr 2012
Results first posted
Apr 20, 2012
Last update
Apr 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00615056
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 14, 2008
Start date
Mar 2008
Primary completion
Mar 2011
Completion
Apr 2012
Results posted
Apr 20, 2012
Last update
Apr 19, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axitinib · Folfox protocol

Start the discussion